BridgeBio Pharma Inc’s filing revealed that its 10% Owner KKR Genetic Disorder L.P. unloaded Company’s shares for reported $149.35 million on Sep 13 ’24. In the deal valued at $25.75 per share,5,800,000 shares were sold. As a result of this transaction, KKR Genetic Disorder L.P. now holds 25,260,971 shares worth roughly $599.19 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, KKR Genetic Disorder L.P. bought 5,800,000 shares, generating $156,310,000 in total proceeds.
Before that, Kumar Neil sold 27,389 shares. BridgeBio Pharma Inc shares valued at $676,256 were divested by the Chief Executive Officer at a price of $24.69 per share. As a result of the transaction, Kumar Neil now holds 4,897,443 shares, worth roughly $116.17 million.
Scotiabank initiated its BridgeBio Pharma Inc [BBIO] rating to a Sector outperform in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early October with a ‘”a Perform”‘ rating. Piper Sandler began covering BBIO with “an Overweight” recommendation on September 04, 2024.
Price Performance Review of BBIO
On Friday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock fall -1.62% to $23.72. Over the last five days, the stock has lost -12.44%. BridgeBio Pharma Inc shares have fallen nearly -41.24% since the year began. Nevertheless, the stocks have fallen -19.65% over the past one year. While a 52-week high of $44.32 was reached on 02/15/24, a 52-week low of $21.62 was recorded on 06/24/24. SMA at 50 days reached $25.50, while 200 days put it at $27.53.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 22.99, which if violated will result in even more drops to 22.27. On the upside, there is a resistance level at 24.37. A further resistance level may holdings at 25.03. The Relative Strength Index (RSI) on the 14-day chart is 41.49, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.78, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.80%. Stochastics %K at 23.11% indicates the stock is a holding.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2024-10-31, dropping by -1.43 million shares to a total of 17.2 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 18.63 million shares. There was a decline of -8.31%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 31, 2024 when BMO Capital Markets began covering the stock and recommended ‘”a Market perform”‘ rating along with a $37 price target.
